Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The COVID-19 pandemic sharpened the disparities in Americans’ access to healthcare resources, particularly those afflicting vulnerable populations.
Teva Pharmaceuticals, in close collaboration with the Morehouse School of Medicine and the Harris Poll group, set out to survey healthcare consumers and healthcare professionals to see how COVID-19 magnified gaps in access to quality healthcare, uncovering insights into related topics such as the barriers to quality healthcare, the increase of mental health diagnoses and the accessibility of telehealth.
This roundtable discussion will focus on the survey’s findings and identify solutions for addressing those gaps, allowing more Americans to enjoy the benefits of our healthcare system.
Teva Pharmaceuticals
Christine Baeder is Senior Vice President, Chief Operating Officer for US Generics at Teva Pharmaceuticals, in which capacity she oversees commercial operations for the nation’s largest supplier of generic medicines. In her twelve-year career at Teva, Christine has held many senior positions in the commercial operations group. Prior to coming to Teva, Christine worked in sales and customer relations at Sandoz. Christine holds a BS in Biology from Wright State University and an MBA from the Fuqua School of Business at Duke University.
Morehouse School of Medicine
In addition to a strong track record in healthcare, Taylor’s 30-year career has included consumer packaged goods, technology, and transportation. Well-known for her on-air and executive leadership roles at CNN and NBC News, she is also a transformational leader with extensive experience in building high performing teams and creating measurable, integrated and value-driven campaigns
King & Spalding LLP
A partner in King & Spalding’s FDA and Life Sciences practice, Eva provides strategic counsel to clients regarding significant and complex issues associated with FDA-regulated biomedical products. Eva draws upon her deep experience with these products at FDA to help clients navigate development, approval, post-market regulation and life-cycle management of drugs and biologics, biosimilars, and combination products.
Executive Editor
Generics Bulletin